Martin Carroll

发表

BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint.

M. Carroll, Jamil Dierov, Raia Dierova, 2004, Cancer cell.

Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia.

M. Carroll, G. Blobel, Gerd A Blobel, 2011, Cancer cell.

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.

Monica L Guzman, M. Carroll, Xiaojie Li, 2008, Blood.

The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells

Francine E. Garrett-Bakelman, Michael G Kharas, Christopher E Mason, 2017, Nature Medicine.

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Pawel Dobrzanski, M. Carroll, P. Dobrzanski, 2008, Blood.

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Omar Abdel-Wahab, Joshua D Rabinowitz, Hilary A Coller, 2010, Cancer cell.

Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP.

Stephen R Master, G. Wertheim, M. Carroll, 2015, Clinical chemistry.

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Iannis Aifantis, Omar Abdel-Wahab, Jacob D. Jaffe, 2012, Cancer cell.

Proteomic and genetic approaches identify Syk as an AML target.

Tina N. Davis, Steven A Carr, William C Hahn, 2009, Cancer cell.

Dynamic evolution of clonal epialleles revealed by methclone

Sheng Li, Francine E. Garrett-Bakelman, Anna L. Brown, 2014, Genome Biology.

An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis

Gail J. Roboz, M. Carroll, G. Roboz, 2008 .